Skip to main content
Premium Trial:

Request an Annual Quote

Opaldia to Offer DiaGenic's Gene Expression Tests in UK

NEW YORK (GenomeWeb News) – Opaldia will distribute DiaGenic’s breast cancer blood test in the UK and will use a research-use-only version of the test in its own studies until the test receives the CE Mark for use in Europe.
 
Opaldia will offer the gene expression test to UK patients under its Breastcare Program. The firm already offers Agendia’s MammaPrint, which is used in disease prognosis, and Agendia's CupPrint, which identifies the origin of metastasized tumors.
 
Diagenic hopes to receive the CE Mark for the breast cancer test by the end of 2008.
 

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.